Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.
Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Darolutamide Shows Consistent Benefits Across Age Groups in Metastatic Prostate Cancer ARASENS Trial Analysis
• Post-hoc analysis of ARASENS trial demonstrates darolutamide plus ADT and docetaxel significantly improved overall survival in both younger and older patients with metastatic hormone-sensitive prostate cancer.
• Treatment efficacy was consistent across age groups, with hazard ratios of 0.70 for patients under 75 and 0.61 for those 75 and older, showing robust survival benefits regardless of age.
• Safety profile remained favorable across age groups, with similar treatment-emergent adverse event rates between darolutamide and placebo arms, though slightly higher frequencies were observed in older patients.
Error parsing response
Error occurred while parsing the model response.
Sanofi's Q3 Sales Surge 15.7% Driven by Vaccines and Dupixent; 2024 EPS Guidance Raised
• Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million.
• Pharma launches, including ALTUVIIIO, Nexviazyme, and Rezurock, saw a significant 67.1% increase, contributing €727 million to the overall sales growth.
• The company's pipeline advanced with four regulatory approvals, including Dupixent for COPD in the US and China, and four positive Phase 3 data readouts, including tolebrutinib for nrSPMS.
• Based on strong Q3 business performance, Sanofi has raised its 2024 business EPS guidance to at least a low single-digit percentage growth at CER.
Lutetium Lu 177 Vipivotide Tetraxetan Shows Promise in Prostate Cancer Treatment
• Lutetium Lu 177 vipivotide tetraxetan has emerged as a significant radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC).
• Studies indicate potential for earlier use of Lutetium Lu 177 vipivotide tetraxetan, before chemotherapy, offering improved tolerability and quality of life for patients.
• Research explores combining Lutetium Lu 177 vipivotide tetraxetan with other therapies, such as androgen receptor pathway inhibitors, to enhance treatment synergy.
• Ongoing trials are investigating novel targets and treatment strategies to address resistance and improve outcomes in advanced prostate cancer.
NICE Rejects AstraZeneca's Lynparza for Prostate Cancer Despite Scottish Approval
• NICE has issued draft guidance rejecting Lynparza (olaparib) for routine NHS use in treating metastatic prostate cancer with BRCA1/2 mutations, citing uncertain evidence and cost-effectiveness concerns.
• The decision creates a treatment disparity across the UK, as Scotland approved Lynparza for prostate cancer in September, highlighting regional differences in drug access.
• At £2,317.50 per pack with an average treatment course costing £37,491, NICE determined that AstraZeneca's economic model failed to demonstrate sufficient benefit to justify the price.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath